3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Increase Fibrinolytic Activity in Rat Aortic Endothelial Cells

Role of Geranylgeranylation and Rho Proteins

From INSERM U 426 and the Department of Physiology, Faculté de Médecine Xavier Bichat, Université Denis Diderot (M.E., D.P., B.E., G.F.), and INSERM U 64, Hopital Tenon (G.N., J.-D.S.), Paris, France.

Correspondence to Dr Marie Essig, INSERM U 426, Faculté de Médecine Xavier Bichat, 16, rue Henri Huchard, F-75018, Paris, France. E-mail essig{at}bichat.inserm.fr

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Abstract—3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (HRIs) have been recently shown to prevent atherosclerosis progression. Clinical benefit results from combined actions on various components of the atherosclerotic lesion. This study was designed to identify the effects of HRI on one of these components, the endothelial fibrinolytic system. Aortas isolated from rats treated for 2 days with lovastatin (4 mg/kg body wt per day) showed a 3-fold increase in tissue plasminogen activator (tPA) activity. In a rat aortic endothelial cell line (SVARECs) and in human nontransformed endothelial cells (HUVECs), HRI induced an increase in tPA activity and antigen in a time- and concentration-dependent manner. In SVARECs, the maximal response was observed when cells were incubated for 48 hours with 50 µmol/L HRI. An increase of tPA mRNA was also in evidence. In contrast, HRI inhibited plasminogen activator inhibitor-1 activity and mRNA. The effects of HRI were reversed by mevalonate and geranylgeranyl pyrophosphate, but not by LDL cholesterol and farnesyl pyrophosphate, and were not induced by -hydroxyfarnesyl phosphonic acid, an inhibitor of protein farnesyl transferase. C3 exoenzyme, an inhibitor of the geranylgeranylated-activated Rho protein, reproduced the effect of lovastatin on tPA and plasminogen activator inhibitor-1 activity and blocked its reversal by geranylgeranyl pyrophosphate. The effect of HRI was associated with a disruption of cellular actin filaments without modification of microtubules. A disrupter of actin filaments, cytochalasin D, induced the same effect as lovastatin on tPA, whereas a disrupter of microtubules, nocodazole, did not. In conclusion, HRI can modify the fibrinolytic potential of endothelial cells, likely via inhibition of geranylgeranylated Rho protein and disruption of the actin filaments. The resulting increase of fibrinolytic activity of endothelial cells may contribute to the beneficial effects of HRI in the progression of atherosclerosis.

Key Words: atherosclerosis • plasminogen activator • isoprenoid • Rho protein • endothelium

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Recent clinical trials have demonstrated that the major function of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (HRIs) is to prevent cardiovascular diseases. HRIs were shown to reduce cardiovascular events in patients suffering from coronary artery diseases,¹ in patients with hypercholesterolemia but no artery disease,² and in patients without hypercholesterolemia.³ HRIs also prevented the progression of atherosclerosis in coronary artery bypass grafts.⁴

HRIs were designed to inhibit the endogenous synthesis of cholesterol, thereby decreasing LDL synthesis in liver, thus leading to a reduction of lipid deposition in arteries and to a delayed growth of atherosclerotic plaques. However, some studies raised the question of the exclusive involvement of the decrease in plasma LDL concentration on the effects of HRIs. Indeed, HRIs induced clinical benefits before any regression in atherosclerotic plaques could be detected,⁵ they diminished cardiovascular mortality even in normocholesterolemic or hypocholesterolemic patients,³ and their effects were different from those observed after reduction of plasma cholesterol levels by surgical therapy.⁶ All these results suggest that the clinical benefit of HRI administration may result from multiple effects on the components of the atherosclerotic lesions. Atherosclerosis and vascular thrombosis result from complex changes and interactions between blood vessels and blood constituents, of which, fibrin deposition and fibrin lysis are major factors.⁷ Fibrinolysis results from the cleavage of fibrin by plasmin, a serine protease that is activated by the plasminogen activators (PAs).⁸ Two physiological PAs have been described, tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). In turn, tPA and uPA activity are tightly regulated by a specific inhibitor, plasminogen activator inhibitor-1 (PAI-1).

Abnormalities such as high fibrinogen levels⁹ or high PAI-1 and low tPA levels¹⁰ have been described in patients with hyperlipoproteinemia. Lipoprotein(a), which reduces tPA-mediated clot lysis,¹¹ and PAI-1 have also been shown to be an independent risk factor for myocardial infarction.¹²

In vivo studies of the effect of HRIs on fibrinolysis, in animals or in humans, led to conflicting results on tPA activity,^{13 14 15} and these discrepant results may be explained by a rapid clearance of PAs and PA/PAI-1 complexes by receptor-mediated endocytosis in the liver.¹⁶ Thus, analysis of plasma tPA and/or PAI-1 activity may not reflect the local modification of the fibrinolytic system, which could regulate the atherosclerotic process.

Since the local fibrinolytic activity in blood vessels is determined to a large extent by the endothelial cell production of tPA and PAI-1,¹⁷ we investigated the effect of HRI on the balance between tPA and PAI-1. We show that HRIs induce an increase of tPA synthesis and release and a decrease in PAI-1 activity. The resulting increase in local fibrinolytic activity may explain the beneficial effects observed with HRIs on atherosclerosis progression.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials
Lovastatin and simvastatin were kindly provided by Merck Sharp & Dohme-Chibret (Rahway, NJ). Mevastatin (compactin), mevalonic acid lactone, LDL cholesterol, farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GGPP), cytochalasin D, nocodazole, mouse monoclonal antibody anti–-tubulin, FITC-conjugated secondary antibody, TRITC-phalloidin, bovine fibrinogen, and bovine thrombin were purchased from Sigma Chemical Co. -Hydroxyfarnesyl phosphonic acid (HFPA) was from Calbiochem. Agarose was from Eurobio. Anti-human uterine tPA and anti-human PAI-1 were from Biopool. SDS and 30% acrylamide/Bis (37:1 and 5:1) solutions were from Bio-Rad. Murine tPA cDNA was a gift from R. Lijnen (Leuven, Belgium). Human PAI-1 cDNA was from D.J. Loskutoff (La Jolla, Calif).¹⁸ Recombinant C3 exoenzyme was a kind gift from M.R. Popoff (Institut Pasteur, Paris, France). Culture media and reagents were from GIBCO-BRL. Plasticware was from Costar.

The molecule of lovastatin was converted to its active form as described by Kita et al.¹⁹ To produce the mevalonate salt, 13 mg of mevalonic acid lactone was incubated in 0.1N NaOH (2 hours, 50°C, pH 7.4); the 0.1 mol/L stock solution was stored at -20°C.

Animal Experiments
Male Wistar rats (Iffa Credo) (160 to 180 g) received once-daily subcutaneous injections of either lovastatin at a dose of 4 mg/kg body wt or the propylene glycol/ethanol (vol/vol) vehicle. Animals were treated for 2 days before they were killed and the aortas were isolated. Blood samples were collected before the animals were killed for study for determination of plasma cholesterol. Each group contained 3 animals.

After isolation, aortas were abundantly rinsed, lysed in a 0.25% Triton X-100/0.1 mol/L Tris HCl (pH 8.1) solution as described by Huarte et al,²⁰ and centrifuged 5 minutes at 14 000g. Supernatants of the lysates were collected and frozen at -20°C until analysis for tPA activity.

Cell Culture
Simian virus 40–transformed rat aortic endothelial cells (SVARECs) were a gift from Dr J.-B. Michel (INSERM U 460, Paris, France). Cells were derived from Sprague-Dawley rats as described previously in detail.²¹ Endothelial cell clones were identified by their typical cobblestone appearance, their capacity to metabolize acetylated LDL, and their positive staining for the von Willebrand factor. The cells were cultured in a medium containing 5% FCS. For experiments, cells were deprived of FCS for 12 hours and then incubated with lovastatin or others drugs in the absence of FCS. At the end of the incubation period, cells supernatants were collected, centrifuged (15 minutes, 14 000g, 4°C), and frozen at -20°C until analysis. Human umbilical vein endothelial cells (HUVECs) were isolated and cultured, as previously described by Jaffe et al,²² in culture medium supplemented with 20% FCS. For experiments, cells were incubated in culture medium containing 1% FCS for 36 hours.

Quantification of tPA
tPA activity present in SVAREC supernatants was quantified by using a chromogenic assay (Spectrolyse/Fibrin, Biopool). Samples were diluted (1:40) and analyzed as described by the manufacturer. To minimize the differences between animals or HUVEC cell numbers, tPA activity in aortic lysates or in HUVEC supernatants was related to protein content of aortic or HUVEC cell lysates.

Statistical analyses of the data were performed using 1-way ANOVA followed by a protected least significant difference test. Statistical significance was accepted at P<0.05.

Zymographies
Zymographies were performed on SVAREC supernatants. One microgram of total proteins was mixed with the gel electrophoresis buffer. After separation on 10% SDS-PAGE, the gel was soaked in Triton X-100 (2.5%) for 1 hour and layered onto a fibrin agarose gel containing bovine plasminogen–enriched fibrinogen (7 mg/mL), bovine thrombin (40 U/mL), and agarose (1%), as previously described by Loskutoff and Schleef.²³ Zymograms were allowed to develop for 12 to 48 hours at 37°C. Plasminogen activator inhibitor activity was detected by reverse fibrin zymography with the addition of uPA (final concentration, 0.5 U/mL) to the fibrin agarose underlay.

Photographs of the gel were scanned by an imaging densitometer and quantified using the NIH Image 1.55 software program. Data are expressed as the mean±SEM in arbitrary units.

Immunoblotting
Immunoblotting of samples obtained from 10-fold concentrated supernatants was carried out by standard techniques. Twenty micrograms of total proteins was mixed with the gel electrophoresis buffer and separated on 10% SDS-PAGE under nonreducing conditions. The proteins were transferred to a nitrocellulose membrane (Bio-Rad). A 10% solution of nonfat dried milk in PBS containing 0.1% Tween 20 (PBST) was used to block nonspecific binding and to dilute the primary and the secondary antibodies. The primary antibody was a polyclonal goat anti-human tPA IgG and a polyclonal goat anti-human PAI-1 (diluted 1:500). After blocking for 1 hour at 37°C, the membrane was incubated for 1 hour at 37°C with the primary antibody, and then the membrane was washed 3 times with PBST, incubated for 1 hour at 37°C with horseradish peroxidase–conjugated secondary antibody (Jackson Immunoresearch Laboratory), and washed 6 times with PBST. Immunoreactive protein bands were detected by the enhanced chemiluminescence method (ECL kit, Amersham).

Protein concentrations were determined by the method of Bradford using the Coomassie protein assay reagent from Pierce.

RNA Isolation and Analysis
RNA was isolated from SVARECs as previously described by Chomczynski and Sacchi.²⁴ Twenty micrograms of total RNA was electrophoresed in 1% agarose denaturing gels containing formaldehyde and transferred overnight to nylon membranes (Hybond N, Amersham). After cross-linking (2 hours at 80°C), membranes were prehybridized for 4 hours at 42°C in hybridization buffer (50% formamide, 6x SSC, 0.5% SDS, and 100 mg/mL salmon sperm DNA). The murine tPA cDNA and the human PAI-1 cDNA were labeled with [³²P]dUTP by in vitro transcription, as described by the manufacturer (Kit Riboprobe Gemini II, Promega), using the T3 polymerase for the tPA cDNA and the T7 polymerase for the PAI-1 cDNA. The membranes were hybridized overnight at 42°C and washed twice with 2x SSC and 0.1% SDS at 25°C and then with 0.1x SSC and 0.1% SDS at 60°C. Autoradiography was performed by standard procedures using X-AR5 films (Kodak) and intensifying screens at -80°C. Radioactivity was quantified using an Instantimager (Packard).

Immunofluorescence
Cells, grown on glass coverslips, were fixed and stained after 24-hour incubation with cytochalasin D, nocodazole, lovastatin, GGPP, or C3 exoenzyme. Cells were washed with PBS, fixed in 4% formaldehyde/PBS for 10 minutes, and permeabilized in Triton X-100 (0.1% in PBS) for 5 minutes at room temperature. Cells were incubated either with TRITC-phalloidin (1:1000 in PBS) for 30 minutes at 37°C or with the monoclonal antibody anti-human -tubulin for 1 hour at 37°C (1:2000 in 1% PBS/BSA) revealed by an FITC-conjugated secondary antibody. After 2 washes in PBS, coverslips were mounted using the Dako Faramount mounting medium. Stained cells were stored in the dark at 4°C until analysis with a Nikon microscope.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
In Vivo Effects of Lovastatin on tPA Activity
Rats treated for 2 days with lovastatin (4 mg/kg per day) showed a slight but nonsignificant decrease in the plasma cholesterol level compared with that of vehicle-treated rats (2.42±0.12 versus 2.18±0.2 mmol/L, P=NS). Moreover, a previous study in the laboratory showed that a similar treatment of lovastatin for 15 days induced a significant decrease in plasma cholesterol values. These 2 results suggested that the treatment with lovastatin was effective.

Isolated aortas showed a 3-fold increase in tPA activity compared with aortas of vehicle-treated rats (0.35±0.05 versus 1.05±0.8 IU/mg protein, P<0.002) (Figure 1). In contrast to tPA, no uPA activity could be detected in aortic lysates.

View larger version (11K): [in this window] [in a new window]   Figure 1. Stimulation of tPA activity in vivo. Aortas were isolated from rats treated or not treated with lovastatin (4 mg/kg per day) and lysed as described in Materials and Methods. tPA activity was quantified by a chromogenic assay and related to protein content of aortic lysates. Results are expressed as percentage of vehicle value. **P<0.002.

Characterization of the Effects of Lovastatin on the Fibrinolytic System of Endothelial Cells
To better characterize the effects of lovastatin on the fibrinolytic activity of endothelial cells, we next performed experiments on a rat aortic endothelial cell line (SVARECs) and on human endothelial cells (HUVECs) as controlled nontransformed cells. SVARECs, as nontransformed endothelial cells, synthesized and released some PAs to promote clot lysis. In SVAREC supernatants, only tPA was observed. No uPA activity could be detected by zymography or by immunoblot. The same pattern of activity was observed in HUVEC supernatants. However, tPA activity was higher in SVAREC supernatant than in HUVEC supernatant (2.88±0.22 versus 0.11±0.006 IU).

As described in other systems,¹⁷ tPA synthesis by SVARECs and HUVECs was affected by the presence of FCS in the medium. Since the effect of FCS could have masked the effects of the HRI, we performed all subsequent experiments on SVARECs after 12 hours of FCS deprivation, and the cells were incubated in medium without FCS. For HUVECs, which could not be serum-starved, we performed the experiments with 1% FCS, the lowest FCS concentration capable of maintaining the viability of HUVECs for 36 hours.

Lovastatin, added to the medium for 48 hours, induced a dramatic increase in tPA activity that was detectable in SVAREC supernatants (control, 2.88±0.22 IU; 25 µmol/L lovastatin, 8.75±0.66 IU; P<0.001). This effect on tPA secretion was observed in the 1- to 50-µmol/L range, with a maximum at 50 µmol/L (Figure 2A), and was reproduced by 2 other HRIs, simvastatin and compactin, in the same range of concentrations (Figure 2A).

View larger version (12K): [in this window] [in a new window]   Figure 2. Concentration-dependent stimulation of tPA activity by HRIs. Increasing concentrations of lovastatin, simvastatin, or compactin were added to confluent cultures of SVARECs or HUVECs for 48 hours. tPA activity was evaluated by a chromogenic assay. A, tPA activity (IU) of SVAREC supernatants. B, tPA activity related to protein content of HUVEC cell lysates. Results are expressed as percentage of control values. Values represent the mean±SE of 3 or 4 independent experiments. *P<0.05 vs control value.

Studies performed on HUVECs showed that lovastatin similarly increased tPA activity (control, 0.457±0.018 IU/mg protein; 5 µmol/L lovastatin, 1.29±0.117 IU/mg protein; P<0.001). Furthermore, the effects were observed for 10-fold lower concentrations of lovastatin in HUVECs compared with SVARECs (Figure 2B).

Time-course studies showed that the increase of tPA due to lovastatin was already detectable after a short incubation time (3 hours) and increased in magnitude with the incubation time, reaching a maximum after 48 hours of incubation (Figure 3).

View larger version (14K): [in this window] [in a new window]   Figure 3. Time course showing stimulation of tPA activity by lovastatin. Confluent SVARECs were incubated in the absence or presence of lovastatin (25 µmol/L). Supernatants were collected after various incubation times and analyzed by zymography.

The increase in tPA activity induced by lovastatin was attributed to an increase in protein expression and not to an increase of tPA-specific activity, since it was accompanied by an increase of tPA antigen visualized by immunoblot: a single band of 68 kDa was detected by immunoblot analysis in control cells and increased in the presence of lovastatin (Figure 4A). This increase was likely the consequence of increased protein synthesis, inasmuch as tPA mRNA content was induced 2.5-fold after 60 minutes of incubation with lovastatin (25 µmol/L) (Figure 4B).

View larger version (19K): [in this window] [in a new window]   Figure 4. Stimulation of tPA protein and mRNA by lovastatin. A, Immunoblot of tPA protein. Confluent SVARECs were incubated with or without lovastatin (25 µmol/L). Supernatants were collected after 6, 24, or 48 hours, concentrated 10-fold, and analyzed by immunoblot with use of a polyclonal anti-tPA antibody. B, Northern blot analysis of tPA mRNA. Confluent SVARECs were incubated with lovastatin (25 µmol/L) for 1 hour before RNA extraction. Localization of the 18S and the 28S RNA, stained by ethidium bromide, was realized by UV illumination of the membrane.

PAI-1 secretion was also affected by lovastatin, which induced a decrease in PAI-1 activity (Figure 5A) and mRNA (Figure 5B). Because of the poor sensitivity of the method, we could not detect PAI-1 antigen by immunoblot. The decrease in PAI-1 activity occurred for the same concentration range of lovastatin. The concomitant increase in tPA and decrease in PAI-1 activities is likely to be synergistic with respect to the stimulation of the fibrinolytic system by lovastatin.

View larger version (45K): [in this window] [in a new window]   Figure 5. Inhibition of PAI-1 activity, antigen, and mRNA by lovastatin. A, PAI-1 activity. Increasing concentrations of lovastatin were added to confluent cultures of SVARECs for 48 hours. The PAI-1 activity present in the supernatant was evaluated by reverse zymography. B, PAI-1 mRNA. Confluent SVARECs were incubated with lovastatin (25 µmol/L) for 0, 30, or 60 minutes before RNA extraction and then analyzed by Northern blot. Localization of the 18S and the 28S RNA, stained by ethidium bromide, was realized by UV illumination of the membrane.

Reversal of the Effects of Lovastatin by Isoprenoids
The effects of lovastatin on tPA activity and protein expression were completely reversed by mevalonate (500 µmol/L), the synthesis of which is catalyzed by HMG CoA reductase, whereas LDL cholesterol (50 µg/mL) did not (control, 3.49±0.06 IU; lovastatin, 12.76±0.782 IU; lovastatin+mevalonate, 3.53±0.53 IU; and lovastatin+LDL cholesterol, 13.99±0.53 IU; P<0.001). These results suggested that the effects of lovastatin involved a modulation of the mevalonate pathway but that end derivatives of the mevalonate pathway, such as cholesterol, were not involved in tPA modulation.

Among the early derivatives synthesized along the mevalonate pathway, the isoprenoids FPP and GGPP are involved in protein regulation by a posttranslational modification leading to the adjunction of the isoprenoids to the COOH terminal part of the protein. To determine whether the effects of lovastatin were mediated by the isoprenylation of a protein, we incubated cells in the presence of lovastatin and of the 2 isoprenoids FPP and GGPP (Figure 6). FPP and GGPP alone did not modify tPA and PAI-1 activity (data not shown). FPP (15 µmol/L) did not abolish tPA increase, and HFPA (15 µmol/L), a competitive inhibitor of the farnesyl transferase, could not reproduce the effects of lovastatin, suggesting that modulation of a farnesylated protein was not involved in tPA regulation. In contrast with FPP, GGPP (15 µmol/L) completely inhibited the augmentation of tPA and the decrease of PAI-1 activity observed with lovastatin (Figure 6A). tPA protein increase was also prevented by GGPP, as shown by the immunoblot analysis (Figure 6C), suggesting the involvement of a geranylgeranylated protein in tPA regulation.

View larger version (37K): [in this window] [in a new window]   Figure 6. Reversal of lovastatin-induced tPA stimulation and PAI-1 inhibition by isoprenoids. SVARECs were incubated with HFPA (15 µmol/L), GGPP (15 µmol/L), and FPP (15 µmol/L) in the presence or absence of lovastatin (25 µmol/L) for 48 hours before cell supernatants were collected for analysis. A, Detection of tPA and PAI-1 activity by zymography and reverse zymography, respectively. B, Quantification of tPA lysis zone (zymography) and PAI-1 lysis protection zone (reverse zymography). Results are the mean of 5 independent experiments. C, Immunoblot of tPA protein.

Interaction With Intracellular Signaling Pathways
Among the isoprenylated small GTP proteins, the Rho and the Rab proteins are known to be mostly geranylgeranylated.²⁵ To determine whether the effects of lovastatin on tPA activity may result from the inhibition of Rho proteins, we incubated cells in the presence of C3 exoenzyme, a specific inhibitor of the Rho proteins²⁶ (Figure 7). C3 exoenzyme (5 µg/mL) induced the same effect as lovastatin on tPA and PAI-1 activity, had no synergistic effects with FPP and lovastatin, and blocked the reversal of the effects of lovastatin by GGPP, suggesting the involvement of Rho proteins. The involvement of other geranylgeranylated proteins different from Rho proteins seemed highly improbable, since C3 exoenzyme completely prevented the effects of GGPP, and GGPP did not modify the effects of C3 exoenzyme on tPA and PAI-1 synthesis.

View larger version (49K): [in this window] [in a new window]   Figure 7. Effect of Rho inhibition on fibrinolysis and reversal of the effects of lovastatin by GGPP. SVARECs were incubated with C3 exoenzyme (5 µg/mL), GGPP (15 µmol/L), and FPP (15 µmol/L) in the presence or absence of lovastatin (25 µmol/L) for 48 hours before cell supernatants were collected for analysis. A, tPA and PAI-1 activity detected by zymography and reverse zymography, respectively. B, Quantification of tPA lysis zone (zymography). Results are the mean of 4 independent experiments.

Modification of the Cytoskeleton
Since Rho proteins are known to regulate the cytoskeletal proteins,²⁷ we evaluated whether the modulation of tPA activity could be accounted for by a modification of the cytoskeleton. Cytochalasin D, a well-known disrupter of the actin filaments, dose-dependently (20 nmol/L to 20 µmol/L) induced an increase in tPA activity. This effect was correlated with the progressive disappearance of the cellular actin stress fibers (Figure 8A). In contrast, nocodazole, which disrupts microtubules, had no effect on tPA activity and actin stress fibers (Figure 8B). Lovastatin (25 µmol/L) induced a disruption of the cellular actin stress fibers compared with control cells, without any modification of the microtubule network (Figure 9). The correlation between the organization of actin filaments and the level of tPA was also reproduced with the GGPP, FPP, and C3 exoenzyme (data not shown). GGPP completely prevented the disappearance of actin stress fibers induced by lovastatin, whereas FPP did not. C3 exoenzyme induced the same disruption of the cellular actin filaments as lovastatin and blocked the reversal of the effect by GGPP. These results may suggest that tPA activity was regulated by the cytoarchitecture of the cells and that the induction of tPA synthesis by lovastatin might result from modifications of the actin filaments.

View larger version (78K): [in this window] [in a new window]   Figure 8. Effect of cytochalasin D and nocodazole on tPA activity and actin filaments. Increasing concentrations of cytochalasin D (0.02 µmol/L to 2 µmol/L) or nocodazole (0.1 µmol/L to 1 µmol/L) were added for 24 hours before supernatants were collected and cells were fixed for immunofluorescence. tPA activity was evaluated by zymography. Organization of actin filaments was analyzed by staining with TRITC-phalloidin. A, Effects of cytochalasin D. B, Effects of nocodazole.

View larger version (127K): [in this window] [in a new window]   Figure 9. Effect of lovastatin on actin filaments and microtubules. SVARECs were incubated for 24 hours with lovastatin (25 µmol/L) before fixation and analysis by immunofluorescence of TRITC-phalloidin or -tubulin staining.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
In the present study, we demonstrated for the first time a direct action of inhibitors of the HMG CoA reductase on the endothelial fibrinolytic system. Lovastatin and 2 other inhibitors, simvastatin and compactin, induced a dramatic increase in the local fibrinolytic system by stimulating tPA expression and activity, an effect that was potentiated by the inhibition of PAI-1. This effect was dependent on geranylgeranylated proteins, which could be the Rho proteins, and was associated with a disruption of the actin filaments.

Although the concentration of lovastatin used in the present study was higher than that observed in the plasma of patients treated with lovastatin (0.01 to 0.5 µmol/L),²⁸ the relevance of the effects observed in this study for patients treated with HRI was supported by several facts. First, the results were observed in vivo with doses of lovastatin previously reported in the treatment of hyperlipidemia in different models of hyperlipidemic rats.^{29 30} Second, the concentration of lovastatin needed to induce tPA activity in nontransformed human endothelial cells (HUVECs) was in the same range as that which inhibits the proliferation of smooth muscle cells,³¹ glomerular mesangial cells,³² and fibroblasts.³³ In SVARECs, higher concentrations of HRIs were necessary to observe the same effects. It is likely that these differences could be accounted for by the higher HMG CoA reductase activity present in simian virus 40–transformed cell lines, such as SVARECs, as demonstrated by Larsson.³⁴

In contrast to the inhibitory effect of lovastatin on proliferation, which was observed after a long incubation period with the drug (24 and 48 hours), stimulation of fibrinolysis was detectable after treatment as short as 2 days and an incubation time of 3 hours.

The fact that simvastatin and compactin, 2 other HRIs, reproduced the effects of lovastatin indicated that the mechanism of the stimulation was related to the inhibition of the mevalonate pathway (which leads to the synthesis of cholesterol) and of a variety of isoprenoid metabolites: dolichol, ubiquinone, and the isoprenoids FPP and GGPP. The complete reversal by mevalonate of the action of lovastatin confirmed this hypothesis.

Since interactions between cholesterol, LDL cholesterol, and fibrinolysis have been suspected for a long time by epidemiological studies¹⁰ or by immunohistological and in situ hybridization analysis of atherosclerotic lesions,³⁵ we first explored the modulation of fibrinolysis exerted by the exogenous precursor of cholesterol, LDL cholesterol. In the present study, incubation of SVARECs with LDL cholesterol did not induce any modification of tPA. Furthermore, LDL cholesterol did not prevent the increase in tPA activity induced by lovastatin. As demonstrated by Steinbrecher et al,³⁶ LDL cholesterol is oxidized by endothelial cells to form oxidized LDL cholesterol. Our results suggested that oxidized LDL did not modulate fibrinolysis in SVARECs and that lovastatin action did not result from an inhibition of oxidized LDL. These results are in agreement with those of Latron et al,³⁷ who did not find any modulation of tPA synthesis by native LDL or oxidized LDL. Results obtained in SVARECs suggest that lovastatin-induced modulation of tPA did not result from a decrease in endogenous cholesterol synthesis and raise the possibility that HRIs could prevent atherosclerosis even in normocholesterolemic patients.

Regarding other metabolites of the mevalonate pathway, we determined that lovastatin action was blocked by GGPP, whereas FPP had no effect. Furthermore, HFPA, a potent inhibitor of farnesyl transferase, did not reproduce lovastatin stimulation of tPA synthesis. FPP and GGPP have been implicated in protein isoprenylation, in the regulation of cell proliferation, and in signal transduction. Prenylated proteins share characteristic C-terminal sequences that determine which of the 2 isoprenoids, FPP or GGPP, is covalently linked to the protein. Since C-terminal sequences of tPA and PAI-1 do not possess such sequences, it is unlikely that these proteins are directly regulated by isoprenylation. The absence of reversal by FPP and the lack of effect of HFPA suggested that p21 ras, the major farnesylated protein that is inhibited by HRIs,³⁸ is not involved in lovastatin action. Indeed, previous studies have rather demonstrated that p21 ras stimulated fibrinolysis.³⁹ In contrast, reversal of the action of lovastatin by GGPP occurred at low concentrations of this metabolite (15 µmol/L) compared with the effective concentration of mevalonate (500 µmol/L), thus suggesting a specific involvement of a geranylgeranylated protein in fibrinolysis modulation. To our knowledge, the present study is the first to demonstrate a direct effect of geranylgeranylated proteins in the regulation of fibrinolysis of endothelial cells.

Among the geranylgeranylated proteins, the Rho family is one of the most important being implicated in various cell functions, such as cell morphology, cell motility, or cytokinesis. We demonstrated that the effect of lovastatin on tPA and PAI-1 was reproduced by the C3 exoenzyme, which inhibits Rho proteins by ADP-ribosylation on asparagine 41 in the effector region of the GTPase.⁴⁰ Furthermore, we determined that C3 exoenzyme blocked the reversal of the effects of lovastatin induced by GGPP, thus suggesting the involvement of the Rho protein family in the action of lovastatin on fibrinolysis.

The mechanism linking Rho proteins to fibrinolysis is not fully elucidated. An involvement of the cytoskeleton is suspected, since Rho proteins are known to regulate the organization of the cytoskeleton and the formation of actin filaments.²⁶ Along this line, Fenton et al⁴¹ and Bifulco et al⁴² demonstrated that HRIs could modify the cytoskeleton organization and the polymerization of intracellular actin. We confirmed on SVARECs that HRIs induced a disruption of the actin filament network without affecting the microtubules. This effect, which was reversed by GGPP, seemed to depend on activated Rho proteins, since it was blocked by C3 exoenzyme. The effects of HRIs on fibrinolysis, on the one hand, and on the disruption of the actin filaments through the inhibition of Rho proteins, on the other hand, are likely to be linked. Indeed, cytochalasin D, which is known to disrupt actin filaments,⁴³ induced the same effect as lovastatin and C3 exoenzyme, whereas nocodazole, which disrupts the microtubules, did not. Along the same line, Snyder et al⁴⁴ demonstrated a stimulation of tPA by dihydrocytochalasin B in F9 teratocarcinoma cells. Moreover, the extensively studied link between cytoskeleton and urokinase^{45 46 47} suggests that modulation of the cytoskeleton could be a potent regulator of tPA synthesis. However, although a link between cytoskeleton reorganization and upregulation of tPA by HRI is suspected, further studies are necessary to assess it definitely.

In conclusion, in the present study, we demonstrated a link between an enhancement of the endothelial fibrinolytic system and the inhibition of the mevalonate pathway by the well-known hypocholesterolemic agents lovastatin, simvastatin, and compactin. The action of the HRIs involved an inhibition of geranylgeranylated proteins, probably the Rho proteins, and was associated with a disruption of the cytoskeleton. These effects, which were observed also in vivo, suggest that HRIs, through the enhancement of local plasmin generation, might prevent fibrin or extracellular matrix deposition in arterial plaques and acute thrombosis in the injured vessel, which are 2 major determinants of the progression of atherosclerosis⁴⁸ and cardiovascular mortality.⁴⁹

	Acknowledgments

 
This study was supported by grants from Institut National de la Santé et de la Recherche Médicale, Center National de la Recherche Scientifique, Université Paris 7, Faculté X- Bichat, Fondation pour la Recherche Médicale, Association pour l'Utilisation du Rein Artificiel, and Laboratoire de recherches Physiologiques.

Received January 7, 1998; accepted June 16, 1998.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.[Medline] [Order article via Infotrieve]
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Ross Lorimer A, MacFarlane PW, Killop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307.[Abstract/Free Full Text]
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Wayne Warnica J, Arnold JAO, Wun CC, Davis BR, Braunwald E, for the cholesterol and recurrent events trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009.[Abstract/Free Full Text]
4. The Post Coronary Artery Bypass Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med. 1997;336:153–162.[Abstract/Free Full Text]
5. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633–638.[Medline] [Order article via Infotrieve]
6. Buchwald H, Campos CT, Boer JR, Nguyen PA, Williams SE. Disease-free interval after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the program on the surgical control of the hyperlipidemia (POSCH). J Am Coll Cardiol. 1995;23:351–357.
7. Tanaka K, Sueishi K. Biology of disease: the coagulation and fibrinolysis system and atherosclerosis. Lab Invest. 1993;69:5–18.[Medline] [Order article via Infotrieve]
8. Vassali JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991;88:1067–1072.
9. Lowe GDO, Drummond MM, Third JLHC, Bremner WF, Forbes CD, Prentice CRM, Laurie TDV. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinemia. Thromb Haemost. 1980;42:1503–1507.[Medline] [Order article via Infotrieve]
10. Jansson JH, Johansson B, Boman K, Nilsson TK. Hypo-fibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med. 1991;229:309–316.[Medline] [Order article via Infotrieve]
11. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res. 1990;57:155–162.[Medline] [Order article via Infotrieve]
12. Hamsten A, Walldius G, Szaposi A, Blomback M, De Farie U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3–9.[Medline] [Order article via Infotrieve]
13. Malyszko J, Urano T, Knöfler R, Takada Y, Takada A. Effects of short-term treatment with mevalotin on platelet aggregation, fibrinolysis, peripheral serotoninergic system and serum lipids in Japanese monkeys. Thromb Res. 1995;81:397–402.
14. Isaacsohn JL, Setaro JF, Nicholas C, Davey JA, Diotalevi LJ, Christianson DS, Liskov E, Stein EA, Black HR. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol. 1994;74:735–737.[Medline] [Order article via Infotrieve]
15. Bevilacqua M, Bettica P, Milani M, Vago T, Rogolino A, Righini V, Santoli E, Norbiato G. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol. 1997;78:84–87.
16. Bu G, Warshawsky I, Schwartz AL. Cellular receptors for the plasminogen activators. Blood. 1994;83:3427–3436.[Free Full Text]
17. Kooistra T, Schrauwen Y, Arts J, Emeis JJ. Regulation of endothelial cell tPA synthesis and release. Int J Hematol. 1994;59:233–255.[Medline] [Order article via Infotrieve]
18. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1986;83:8776–8780.
19. Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest. 1980;66:1094–1100.
20. Huarte J, Belin D, Vassalli J. Plasminogen activator in mouse and rat oocytes: induction during meiotic maturation. Cell. 1985;43:551–558.[Medline] [Order article via Infotrieve]
21. Charreau B, Cassard A, Tesson L, Le Mauff B, Navenot JM, Blanchard D, Lublin D, Soulillou JP, Anegon I. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation. 1994;58:1222–1229.[Medline] [Order article via Infotrieve]
22. Jaffe E, Nachman R, Becker C, Minich C. Culture of human endothelial cells derived from umbilical veins. J Clin Invest. 1973;52:2745–2756.
23. Loskutoff DJ, Schleef RR. Plasminogen activators and their inhibitors. Methods Enzymol. 1988;163:293–302.[Medline] [Order article via Infotrieve]
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159.[Medline] [Order article via Infotrieve]
25. Adamson P, Marshall CJ, Hall A, Tilbrook PA. Posttranslational modification of p21rho proteins. J Biol Chem. 1992;267:20033–20038.[Abstract/Free Full Text]
26. Chardin P, Bocquet P, Madaule P, Popoff MR, Rubin EJ, Gill DM. The mammalian G protein RhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilaments in vero cells. EMBO J. 1989;8:1087–1092.[Medline] [Order article via Infotrieve]
27. Ridley AJ, Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesion and actin stress fibers in response to growth factor. Cell. 1992;70:389–399.[Medline] [Order article via Infotrieve]
28. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet. 1996;31:348–371.[Medline] [Order article via Infotrieve]
29. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res. 1988;62:367–374.[Abstract/Free Full Text]
30. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988;33:667–672.[Medline] [Order article via Infotrieve]
31. Munro E, Patel M, Chan P, Betteridge L, Clunn G, Gallagher K, Hughes A, Schachter M, Wolfe J, Sever P. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest. 1994;24:766–772.[Medline] [Order article via Infotrieve]
32. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993;91:83–87.
33. Larsson O, Barrios C, Latham C, Ruiz J, Zetterberg A, Zickert P, Wejde J. Abolition of mevinolin-induced growth inhibition in human fibroblasts following transformation by simian virus 40. Cancer Res. 1989;49:5605–5610.[Abstract/Free Full Text]
34. Larsson O. Effect of virus-transformation and growth factor stimulation on isoprene biosynthesis in human fibroblasts: a correlation to cell growth. Cancer Biochem Biophys. 1995;14:243–256.[Medline] [Order article via Infotrieve]
35. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO. Plasminogen activator expression in human advanced atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1995;15:1444–1455.[Abstract/Free Full Text]
36. Steinbrecher UP, Parthasarathy S, Leake DS, Wiztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883–3887.[Abstract/Free Full Text]
37. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb. 1991;11:1821–1829.[Abstract/Free Full Text]
38. Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A. 1989;8866:8323–8327.
39. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem. 1995;270:23007–23012.[Abstract/Free Full Text]
40. Aktories K. Bacterial toxins that target Rho proteins. J Clin Invest. 1997;99:827–829.[Medline] [Order article via Infotrieve]
41. Fenton RG, Kung HF, Longo DL, Smith MR. Regulation of intracellular actin polymerization by prenylated cellular proteins. J Cell Biol. 1992;117:347–356.[Abstract/Free Full Text]
42. Bifulco M, Laezza C, Aloj SM, Garbi C. Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J Cell Physiol. 1993;155:340–348.[Medline] [Order article via Infotrieve]
43. Iimura O, Vrtovsnik F, Terzi F, Friedlander G. HMG CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture. Kidney Int. 1997;52:962–972.[Medline] [Order article via Infotrieve]
44. Snyder RW, Lenburg ME, Seebaum AT, Grabel LB. Disruption of the cytoskeleton-extracellular matrix linkage promotes the accumulation of plasminogen activators in F9 derived parietal endoderm. Differentiation. 1992;50:153–162.[Medline] [Order article via Infotrieve]
45. Botteri FM, Ballmer-Hofer K, Rajput B, Nagamine Y. Disruption of cytoskeletal structures results in the induction of the urokinase-type plasminogen activator gene expression. J Biol Chem. 1990;265:13327–13334.[Abstract/Free Full Text]
46. Lee JS, von der Ahe D, Kiefer B, Nagamine Y. Cytoskeletal reorganisation and TAP differently modify AP-1 to induce the urokinase-type plasminogen activator gene in LLC-PK1 cells. Nucleic Acids Res. 1995;21:3365–3372.[Abstract/Free Full Text]
47. Irigoyen JP, Besser D, Nagamine Y. Cytoskeleton reorganisation induces the urokinase-type plasminogen activator gene via the ras/extracellular signal-regulated kinase (ERK) signaling pathway. J Biol Chem. 1997;272:1904–1909.[Abstract/Free Full Text]
48. Thyberg J, Hedin U, Sjvlind M, Palmberg M, Bottger BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis. 1990;10:966–990.[Free Full Text]
49. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery diseases and the acute coronary syndrome. N Engl J Med. 1992;326:242–250/310–318.[Medline] [Order article via Infotrieve]